Log in to save to my catalogue

Cell-bound complement activation products associate with lupus severity in SLE

Cell-bound complement activation products associate with lupus severity in SLE

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_7e553cd240b74e2a99f63c641ba94073

Cell-bound complement activation products associate with lupus severity in SLE

About this item

Full title

Cell-bound complement activation products associate with lupus severity in SLE

Publisher

England: Lupus Foundation of America

Journal title

Lupus science & medicine, 2020-04, Vol.7 (1), p.e000377

Language

English

Formats

Publication information

Publisher

England: Lupus Foundation of America

More information

Scope and Contents

Contents

ObjectivesTo evaluate the association between lupus severity and cell-bound complement activation products (CB-CAPs) or low complement proteins C3 and C4.MethodsAll subjects (n=495) fulfilled the American College of Rheumatology (ACR) classification criteria for SLE. Abnormal CB-CAPs (erythrocyte-bound C4d or B-lymphocyte-bound C4d levels >99th per...

Alternative Titles

Full title

Cell-bound complement activation products associate with lupus severity in SLE

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_7e553cd240b74e2a99f63c641ba94073

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_7e553cd240b74e2a99f63c641ba94073

Other Identifiers

ISSN

2053-8790

E-ISSN

2053-8790

DOI

10.1136/lupus-2019-000377

How to access this item